ArticleOncoimmunology
Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Modular (universal) CAR-T platformsFrontiers in immunology · 2024Pooled it
- Targeting urological cancers with CAR-T cell therapy: current landscape and future directions.Journal of translational medicine · 2026Review
- CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges.Nature reviews. Gastroenterology & hepatology · 2025Review
- Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters.Nature communications · 2024Article
- Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.Oncology research · 2024Review
- Switchable CAR T cell strategy against osteosarcoma.Cancer immunology, immunotherapy : CII · 2023Article
- Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells.Journal of hematology & oncology · 2023Article
- Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.Journal of translational medicine · 2023Review
- Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy.Frontiers in pharmacology · 2023Article
- Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.Journal for immunotherapy of cancer · 2022Article
- The antigen-binding moiety in the driver's seat of CARs.Medicinal research reviews · 2022Review
- Next-generation CAR T cells to overcome current drawbacks.International journal of hematology · 2021Review
- Article
- Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.Oncoimmunology · 2021Article
- Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.Molecular therapy oncolytics · 2020Article
- Review
- Recent Advances in Allogeneic CAR-T Cells.Biomolecules · 2020Review
- MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells.Journal of hematology & oncology · 2019Article
- Engineering switchable and programmable universal CARs for CAR T therapy.Journal of hematology & oncology · 2019Review
- From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cellsOncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The universal modular chimeric antigen receptor (UniCAR) platform redirects CAR-T cells using a separated, soluble targeting module with a short half-life. This segregation allows precise controllability and flexibility. Herein we show that the UniCAR platform can be used to efficiently target solid cancers
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.